Introduction
============

Human immunodeficiency virus (HIV), which was first discovered in 1981, has now infected more than two million people in India. The introduction of antiretroviral therapy (ART) has resulted in significant reductions in mortality and morbidity of these patients. However, the occurrence of insulin resistance and metabolic syndrome has been reported as a side effect of this therapy.[@b1-ijgm-4-073] The drugs implicated include nucleoside reverse transcriptase inhibitors (major components of first-line therapy in India) and also protease inhibitors (components of current second-line therapy in India). With alteration in insulin sensitivity, dysglycemia, dyslipidemia, hypertension, and body fat abnormalities, there are concerns about the long-term risks of ART.[@b2-ijgm-4-073] In India, where there is genetic predisposition to insulin resistance and cardiovascular risk,[@b3-ijgm-4-073],[@b4-ijgm-4-073] this impact may be significant. Hence, this study was undertaken to assess the prevalence of these conditions in HIV-infected patients.

The aims of the study were to: 1) estimate the prevalence of metabolic syndrome, insulin resistance, and diabetes mellitus in HIV-infected patients on ART; and 2) compare the prevalence of these conditions between patients who are on ART and those who are ART-naïve.

Methods
=======

This is a cross-sectional study involving HIV-positive patients conducted in a tertiary referral centre in Bangalore. Patients were enrolled into the study if they were aged over 18 years, had HIV infection for more than 12 months, and were on ART (ART-treated group) or had HIV infection for more than 12 months but were not on ART (ART-naïve group). Patients were not included in the study if diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, malignancy, sleep apnea, or chronic renal failure were present prior to starting ART or if they were nonadherent to ART.

Patients who satisfied the criteria were informed of the study and its details, following which a consent form was signed. The demographic details were collected from each patient and entered into the pro-forma. Subsequent to this, a detailed history was taken, and a thorough physical examination was done. The anthropometric measurements were done by a skilled nutritionist, and these were height, weight, and waist circumference, measured using height scale, weighing machine, and inch tape, respectively, standardized regularly in the St. John's Medical College Nutrition Research Centre. Height was recorded to the nearest centimeter, and weight was recorded to the nearest 0.5 kg. Waist girth was measured at the point between the iliac crest and the lower margin of the ribs and rounded to the nearest centimeter.

After an overnight fast, blood samples were drawn from each patient. Following this, 75 g glucose was administered, and at 2 hours another blood sample was drawn. Blood glucose levels, both fasting and post glucose load, were estimated using the hexokinase (enzymatic) method spectrophotometrically in R×L dimension automated equipment. The total cholesterol was determined using the cholesterol oxidase and cholesterol esterase method. High-density lipoprotein (HDL) cholesterol was estimated by the automated enzymatic method. Triglycerides were determined using the lipoprotein lipase/glucokinase enzymatic procedure. The lipid profile was estimated using Dade Behring equipment. Fasting insulin levels were done using chemiluminescence method on immulite equipment from Diagnostics Product Corporation (Kolkata, India). All biochemical procedures were done in accordance with the International Federation of Clinical Chemistry (IFCC) quality control. The lab is under internal and external quality control and is National Accreditation Board for Testing and Calibration Laboratories (NABL)-accredited. CD-4 counts were done in the department of microbiology or private labs.

Metabolic syndrome was defined using National Cholesterol Education Program--Adult Treatment Plan III (NCEP--ATP III) 2001 criteria.[@b5-ijgm-4-073] If three or more of the following criteria were present, metabolic syndrome was diagnosed:

-   Waist circumference more than 102 cm in men and 88 cm in women,

-   Triglycerides more than 150 mg/dL,

-   HDL cholesterol less than 40 mg/dL in men and less than 50 mg/dL in women,

-   Blood pressure more than or equal to 130/85 mm Hg,

-   Fasting glucose more than 110 mg/dL.

Insulin resistance (IR) was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR). This was obtained using the formula:[@b6-ijgm-4-073]
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A cutoff value of 1.93 was taken as IR, based on the Chennai Urban Population Study.[@b7-ijgm-4-073]

Diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance
---------------------------------------------------------------------------

The following criteria were used to classify hyperglycemia:[@b8-ijgm-4-073]

-   Fasting plasma glucose (FPG) \< 100 mg/dL (5.6 mmol/L) = normal fasting glucose,

-   FPG 100--125 mg/dL (5.6--6.9 mmol/L) = impaired fasting glucose (IFG),

-   FPG ≥ 126 mg/dL (7.0 mmol/L) = provisional diagnosis of diabetes.

The corresponding categories when the oral glucose tolerance test (OGTT) is used are the following:

-   Two-hour postload glucose \<140 mg/dL (7.8 mmol/L) = normal glucose tolerance,

-   Two-hour pos t load glucose 140--199 mg/dL (7.8--11.1 mmol/L) = IGT (impaired glucose tolerance),

-   Two-hour postload glucose ≥200 mg/dL (11.1 mmol/L) = provisional diagnosis of diabetes.

Ethics
------

Approval from the Institutional Ethics Review Board was obtained prior to commencement of the study. All patients were provided with details of the aims of the study and the procedure following enrollment. A consent form was signed by all patients who were included in the study.

Statistics
----------

The data were analyzed using SPSS software (version 16; SPSS Inc., Chicago, IL). Student's *t*-test was done to compare numerical variables in the two groups. Chi square test or Fisher's exact test were used for ordinal variables.

Results
=======

A total of 60 patients were enrolled in the study. Of these, 30 patients were ART-naïve, and 30 were treated with ART. The mean duration of ART was 41.5 months (range 12--108 months). There were 23 males and seven females in the ART-treated group and 21 males and nine females in the ART-naïve group. The mean age of patients in the ART-treated group was 41.63 (±10.94), while that in the ART group was 40.6 (±9.48). The mean duration of disease (HIV) was 53.3 (±27.76) months in the ART-treated group and 17.20 (±9.18) months in the ART-naïve group. [Table 1](#t1-ijgm-4-073){ref-type="table"} summarizes demographic details, components of metabolic syndrome, insulin resistance, and CD-4 counts in the ART-treated and ART-naïve groups.

Applying NCEP--ATP III criteria, a total of 16 patients out of 60 were diagnosed to have metabolic syndrome. Of these, 13 (81.3%) were on ART, while three (18.7%) were not treated with ART (*P* = 0.028). Of the 60 patients, all had at least one component of metabolic syndrome. Four patients fulfilled four criteria, and all of them were on ART. The details of the number of patients with combinations of criteria are demonstrated in [Figure 1](#f1-ijgm-4-073){ref-type="fig"}. The majority of patients with metabolic syndrome were males (12/16). When the patients with metabolic syndrome were grouped into two, based on age (age ≤40 years and age \>40 years), nine were aged 40 years or younger. Four patients with metabolic syndrome had body mass index (BMI) less than 18.5, 10 had BMI ranging from 18.5 to 24.9, and two had BMI more than 25. There was none in the obese range with BMI above 30. Among the parameters used for diagnosis of metabolic syndrome, the most observed was low HDL, occurring in all patients. The details of distribution of individual components in patients with metabolic syndrome are graphically represented in [Figure 2](#f2-ijgm-4-073){ref-type="fig"}.

For evaluating the occurrence of metabolic syndrome with respect to the type of ART, the patients were classified into three groups: 1) nonprotease inhibitor (PI), nonstavudine (d4T), 2) non-PI d4T, and 3) PI-based regimens. Of the 30 patients in the ART group, three were exposed to PIs, 18 to d4T, and nine received the non-PI, non-d4T regime. All three patients exposed to PI had metabolic syndrome. In the non-PI d4T group, 6 out of 18 had metabolic syndrome, and in the non-PI, non-d4T group 4 out of 9 had metabolic syndrome.

IR was detected in 24 (40%) patients in the study group with a cutoff value of 1.93 for HOMA. Of these, 15 (62.5%) were on ART, while nine (37.5%) were ART naïve (*P* = 0.11). Thirteen were aged 40 years or less, whereas the rest were over this age. Eighteen patients with IR were male, and six female. In patients with IR, BMI in seven patients was less than 18.5, and in 13 patients, between 18.5 and 24.9. Two patients with IR had BMI in the 25.0--29.9 range, and two were obese with BMI over 30. IR was present in 12 out of 16 patients (75%) with metabolic syndrome. Looking at various treatment regimens, all three patients in the PI group had IR. In the d4T group, seven out of 18, and in the non-d4T group, five out of nine had IR.

In the ART-naïve group, five patients had IFG, two had IGT, and two had diabetes. In the ART-treated group, three had IFG, two had IGT, two had both IFG and IGT, and six had diabetes.

Discussion
==========

The results of the study show that there is an increased prevalence of metabolic syndrome and IR in patients treated with ART. In our study, the overall prevalence of metabolic syndrome in HIV-positive patients was 26.6%; 43.3% in the ART-treated group, and 10% in the ART-naïve group. These results showed a statistically significant increase in the ART group (*P* = 0.028). Studies from Spain and other parts of the world have reported prevalence rates of 17%--18% on larger HIV populations using NCEP--ATP III criteria.[@b9-ijgm-4-073],[@b10-ijgm-4-073] Indian studies on uninfected individuals have reported prevalence rates ranging from 18.4% to 30.9% using NCEP--ATP III criteria.[@b11-ijgm-4-073],[@b12-ijgm-4-073] Thus, in our study the overall prevalence rate appears to be similar to the Indian general population but higher than other HIV populations. The prevalence in our ART-treated group is much higher at 43.3%. Insulin resistance based on HOMA values was present in 75% of our patients with metabolic syndrome, thereby reiterating its pivotal role in its pathogenesis of this condition.

It is of interest that all the patients included in the study had at least one criterion for metabolic syndrome, and the most observed was low HDL. In the Spanish study, of the total 710 study patients (both ART-treated and -naïve), one or more criteria were fulfilled by 69.3%, two or more by 35.8%, three or more by 17%, four or more by 4.5%, and all five criteria were seen only in one patient.[@b9-ijgm-4-073] Though not directly comparable, these results suggest that unlike in our patients, 31.7% did not have any feature of metabolic syndrome, implying that these metabolic derangements may be more prevalent in the Indian population. In our study, low HDL cholesterol was the most observed parameter, whereas in the Spanish study, hypertriglyceridemia was the most commonly recognized. Despite this difference, the dyslipidemia observed in our patients is concordant with HIV associated dyslipidemia and is a confirmed risk factor for macrovascular disease.[@b13-ijgm-4-073]

The mechanism of IR and metabolic syndrome in nucleoside reverse transcriptase inhibitor-treated patients is postulated to be mitochondrial toxicity.[@b14-ijgm-4-073] It should be kept in mind here that affluent nations have moved on to less toxic drugs, while developing countries like India still administer these drugs as part of national treatment programs. [@b15-ijgm-4-073] The individual contributions of drugs could not be assessed in our study due to inadequate numbers of patients, though 10 out of 27 patients on nucleoside reverse transcriptase inhibitor-based regimes had metabolic syndrome, and 12 out of 27 had IR. All the three patients on protease inhibitors in our ART-treated group had metabolic syndrome and IR.

Both fasting and post-glucose load blood glucose values suggest a high proportion of patients with dysglycemia, with six patients in the ART group satisfying diagnostic criteria for diabetes. In the context of high usage of nucleoside reverse transcriptase inhibitors in our ART regimes, such results appear alarming. It is to be noted here that nucleoside reverse transcriptase inhibitors used as first-line drugs in India have been strongly implicated in the development of insulin resistance and subsequent diabetes.[@b16-ijgm-4-073]

The number of patients with metabolic syndrome in the ART-naïve group was three out of a total of 30. One notable difference between ART-treated and ART-naïve patients was the duration of disease. However, this bias cannot be fully eliminated as it is unethical to deny therapy to patients whose CD4 counts fall to recommended levels to commence therapy. It is also of note that, 9 out of 24 patients who had IR were not on ART, while 15 were. In addition, dysglycemia was observed in nine patients in the ART group. While mitochondrial toxicity is responsible for IR in nucleoside reverse transcriptase inhibitor-treated patients, HIV proteins Tat, Vpr, Vif, Rev, and Nef, as well as inflammatory cytokines interleukin-2 and tumor necrosis factor-α are implicated in ART-naïve patients.[@b1-ijgm-4-073]

The BMI of our patients, both with metabolic syndrome and insulin resistance, was mostly in the range 18.5--24.9, in keeping with the lean fat Indian phenotype with central obesity. [@b4-ijgm-4-073] The ages of patients with IR and metabolic syndrome show a tendency towards younger groups, in contrast to Western studies where mean age of HIV-infected patients with these conditions is higher.[@b9-ijgm-4-073],[@b10-ijgm-4-073] The increased cardiovascular risk for South Asians with central obesity has been extensively studied.[@b3-ijgm-4-073],[@b4-ijgm-4-073] Also, the future risk for development of diabetes and cardiovascular risk in patients with metabolic syndrome is well established.[@b17-ijgm-4-073] An increased cerebro- and cardiovascular risk due to metabolic syndrome in HIV has been observed by the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.[@b2-ijgm-4-073] However, in a risk-prone Indian population, the additional burden conferred by ART/ HIV-induced metabolic syndrome needs to be evaluated. If proven, this will have implications on future drug policies for HIV-infected patients.

Despite the limitation of the small number of patients in our study, there is an increase in metabolic syndrome, diabetes mellitus, and insulin resistance in patients on ART in southern India. Larger population-based studies are needed to assess the actual prevalence of metabolic syndrome and IR and the macrovascular risk conferred by these conditions.
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###### 

Comparison between ART-treated and ART-naïve groups

  Study characteristic                  ART (n = 30)   ART-naïve (n = 30)   *P* value            
  ------------------------------------- -------------- -------------------- ----------- -------- ---------
  Age (years)                           41.63          10.94                40.60       9.48     0.697
  Duration of disease (months)          53.03          27.76                17.20       9.18     \<0.001
  Male/female                           23/7           --                   21/9        --       --
  BMI (kg/m^2^)                         20.27          3.82                 18.41       4.27     0.080+
  Waist circumference (cm)              82.7           11.88                76.7        9.64     0.036
  Systolic BP (mm Hg)                   125.67         18.51                114.13      11.60    0.005
  Diastolic BP (mm Hg)                  80.60          9.13                 75.60       8.23     0.030
  Fasting blood glucose (mg/dL)         95             25.16                89.53       19.6     0.352
  Two-hour OGTT blood glucose (mg/dL)   111.33         58.47                131.33      28.55    0.094
  HOMA                                  2.50           2.68                 1.80        1.93     0.265
  Total cholesterol (mg/dL)             157.47         43.58                149.17      39.92    0.445
  HDL cholesterol (mg/dL)               32.87          13.27                25.53       9.42     0.017
  LDL cholesterol (mg/dL)               86.92          32.91                78.50       21.63    0.281
  Triglycerides (mg/dL)                 201.37         163.66               155.43      70.14    0.163
  CD-4 counts (cells/μL)                210.23         172.89               170.67      131.40   0.322

**Abbreviations:** ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA, homeostasis assessment; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; SD, standard deviation.
